Browsing Tag
Catalio Capital Management
2 posts
Can Ratio Therapeutics turn a $70m funding round into a scalable cancer-treatment platform?
Ratio Therapeutics’ Series C financing gives the Boston oncology company additional capital to advance [Ac-225]RTX-2358, bring another radioligand therapy into clinical development and expand the manufacturing network needed to support a broader cancer pipeline.
July 31, 2026
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.
June 8, 2026